Literature DB >> 11839817

Identification of Akt association and oligomerization domains of the Akt kinase coactivator TCL1.

Gerald Künstle1, Jarmo Laine, Gaelle Pierron, Shin-ichiro Kagami Si, Hiroshi Nakajima, Francois Hoh, Christian Roumestand, Marc-Henri Stern, Masayuki Noguchi.   

Abstract

Serine/threonine kinase Akt/protein kinase B, the cellular homologue of the transforming viral oncogene v-Akt, plays a central role in the regulation of cell survival and proliferation. We have previously demonstrated that the proto-oncogene TCL1 is an Akt kinase coactivator. TCL1 binds to Akt and mediates the formation of oligomeric TCL1-Akt high-molecular-weight protein complexes in vivo. Within these protein complexes, Akt is preferentially phosphorylated and activated. The MTCP1/TCL1/TCL1b oncogene activation is the hallmark of human T-cell prolymphocytic leukemia (T-PLL), a form of adult leukemia. In the present study, using a PCR-generated random TCL1 library combined with a yeast two-hybrid screening detecting loss of interaction, we identified D16 and I74 as amino acid residues mediating the association of TCL1 with Akt. Based on molecular modeling, we determined that the beta C-sheet of TCL1 is essential for TCL1 homodimerization. Studies with mammalian overexpression systems demonstrated that both Akt association and oligomerization domains of TCL1 are distinct functional domains. In vitro kinase assays and overexpression experiments in mammalian cells demonstrated that both TCL1-Akt interaction and oligomerization of TCL1 were required for TCL1-induced Akt activation and substrate phosphorylation. Assays for mitochondrial permeability transition, nuclear translocation, and cell recovery demonstrated that both Akt association and homodimerization of TCL1 are similarly needed for the full function of TCL1 as an Akt kinase coactivator in vivo. The results demonstrate the structural basis of TCL1-induced activation of Akt, which causes human T-PLL.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11839817      PMCID: PMC134690          DOI: 10.1128/MCB.22.5.1513-1525.2002

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  52 in total

1.  Akt/protein kinase B is regulated by autophosphorylation at the hypothetical PDK-2 site.

Authors:  A Toker; A C Newton
Journal:  J Biol Chem       Date:  2000-03-24       Impact factor: 5.157

2.  Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor.

Authors:  A Brunet; A Bonni; M J Zigmond; M Z Lin; P Juo; L S Hu; M J Anderson; K C Arden; J Blenis; M E Greenberg
Journal:  Cell       Date:  1999-03-19       Impact factor: 41.582

3.  The role of 3-phosphoinositide-dependent protein kinase 1 in activating AGC kinases defined in embryonic stem cells.

Authors:  M R Williams; J S Arthur; A Balendran; J van der Kaay; V Poli; P Cohen; D R Alessi
Journal:  Curr Biol       Date:  2000-04-20       Impact factor: 10.834

4.  A human protein kinase Bgamma with regulatory phosphorylation sites in the activation loop and in the C-terminal hydrophobic domain.

Authors:  D Brodbeck; P Cron; B A Hemmings
Journal:  J Biol Chem       Date:  1999-04-02       Impact factor: 5.157

5.  Direct random mutagenesis of gene-sized DNA fragments using polymerase chain reaction.

Authors:  M Fromant; S Blanquet; P Plateau
Journal:  Anal Biochem       Date:  1995-01-01       Impact factor: 3.365

6.  Abnormalities at 14q32.1 in T cell malignancies involve two oncogenes.

Authors:  Y Pekarsky; C Hallas; M Isobe; G Russo; C M Croce
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-16       Impact factor: 11.205

Review 7.  The PI3K-PDK1 connection: more than just a road to PKB.

Authors:  B Vanhaesebroeck; D R Alessi
Journal:  Biochem J       Date:  2000-03-15       Impact factor: 3.857

8.  Involvement of the pleckstrin homology domain in the insulin-stimulated activation of protein kinase B.

Authors:  C L Sable; N Filippa; C Filloux; B A Hemmings; E Van Obberghen
Journal:  J Biol Chem       Date:  1998-11-06       Impact factor: 5.157

9.  Tcl1 enhances Akt kinase activity and mediates its nuclear translocation.

Authors:  Y Pekarsky; A Koval; C Hallas; R Bichi; M Tresini; S Malstrom; G Russo; P Tsichlis; C M Croce
Journal:  Proc Natl Acad Sci U S A       Date:  2000-03-28       Impact factor: 11.205

10.  Regulation of TCL1 expression in B- and T-cell lymphomas and reactive lymphoid tissues.

Authors:  M G Narducci; E Pescarmona; C Lazzeri; S Signoretti; A M Lavinia; D Remotti; E Scala; C D Baroni; A Stoppacciaro; C M Croce; G Russo
Journal:  Cancer Res       Date:  2000-04-15       Impact factor: 12.701

View more
  26 in total

1.  Tcl1 interacts with Atm and enhances NF-κB activation in hematologic malignancies.

Authors:  Eugenio Gaudio; Riccardo Spizzo; Francesco Paduano; Zhenghua Luo; Alexey Efanov; Alexey Palamarchuk; Amanda S Leber; Mohamed Kaou; Nicola Zanesi; Arianna Bottoni; Stefan Costinean; Laura Z Rassenti; Tatsuya Nakamura; Thomas J Kipps; Rami I Aqeilan; Yuri Pekarsky; Francesco Trapasso; Carlo M Croce
Journal:  Blood       Date:  2011-11-07       Impact factor: 22.113

2.  Peptide-mediated activation of Akt and extracellular regulated kinase signaling prevents lymphocyte apoptosis.

Authors:  Jonathan E McDunn; Jared T Muenzer; Latif Rachdi; Katherine C Chang; Chris G Davis; W Michael Dunne; David Piwnica-Worms; Ernesto Bernal-Mizrachi; Richard S Hotchkiss
Journal:  FASEB J       Date:  2007-09-13       Impact factor: 5.191

3.  Nerve growth factor regulates the expression of the cholinergic locus and the high-affinity choline transporter via the Akt/PKB signaling pathway.

Authors:  Beata Madziar; Sonia Shah; Martina Brock; Rebecca Burke; Ignacio Lopez-Coviella; Ann-Christin Nickel; Esra Betul Cakal; Jan Krzysztof Blusztajn; Brygida Berse
Journal:  J Neurochem       Date:  2008-09-13       Impact factor: 5.372

4.  The TCL1 function revisited focusing on metabolic requirements of stemness.

Authors:  Maria Teresa Fiorenza; Alessandro Rava
Journal:  Cell Cycle       Date:  2019-09-29       Impact factor: 4.534

5.  Dysregulated TCL1 promotes multiple classes of mature B cell lymphoma.

Authors:  Katrina K Hoyer; Samuel W French; Devin E Turner; Mai T N Nguyen; Mathilde Renard; Cindy S Malone; Sonja Knoetig; Chen-Feng Qi; Thomas T Su; Hilde Cheroutre; Randolph Wall; David J Rawlings; Herbert C Morse; Michael A Teitell
Journal:  Proc Natl Acad Sci U S A       Date:  2002-10-14       Impact factor: 11.205

Review 6.  Recent development of anticancer therapeutics targeting Akt.

Authors:  John K Morrow; Lei Du-Cuny; Lu Chen; Emmanuelle J Meuillet; Eugene A Mash; Garth Powis; Shuxing Zhang
Journal:  Recent Pat Anticancer Drug Discov       Date:  2011-01       Impact factor: 4.169

7.  1H, 15N and 13C chemical shift assignments of the Pleckstrin Homology domain of the Human Protein Kinase B (PKB/Akt).

Authors:  Daniel Auguin; Philippe Barthe; Marie-Thérèse Augé-Sénégas; François Hoh; Masayuki Noguchi; Christian Roumestand
Journal:  J Biomol NMR       Date:  2003-11       Impact factor: 2.835

8.  Epstein-Barr virus nuclear protein 3C domains necessary for lymphoblastoid cell growth: interaction with RBP-Jkappa regulates TCL1.

Authors:  Sungwook Lee; Shuhei Sakakibara; Seiji Maruo; Bo Zhao; Michael A Calderwood; Amy M Holthaus; Chiou-Yan Lai; Kenzo Takada; Elliott Kieff; Eric Johannsen
Journal:  J Virol       Date:  2009-09-23       Impact factor: 5.103

9.  High TCL1 expression and intact T-cell receptor signaling define a hyperproliferative subset of T-cell prolymphocytic leukemia.

Authors:  Marco Herling; Kaushali A Patel; Michael A Teitell; Marina Konopleva; Farhad Ravandi; Ryuji Kobayashi; Dan Jones
Journal:  Blood       Date:  2007-09-21       Impact factor: 22.113

10.  Unscheduled Akt-triggered activation of cyclin-dependent kinase 2 as a key effector mechanism of apoptin's anticancer toxicity.

Authors:  Subbareddy Maddika; Soumya Panigrahi; Emilia Wiechec; Sebastian Wesselborg; Ute Fischer; Klaus Schulze-Osthoff; Marek Los
Journal:  Mol Cell Biol       Date:  2008-12-22       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.